Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × betrixaban × Classical hematology × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Venous Thromboembolism 1

Interventions

fludarabine phosphate 50 Cyclophosphamide 48 Epoetin Alfa 40 Cyclosporine 37 Busulfan 36 Peripheral Blood Stem Cell Transplantation 30 Darbepoetin alfa 30 Mycophenolic Acid 27 Cytarabine 27 Whole-Body Irradiation 26 Filgrastim 24 Antilymphocyte Serum 24 Melphalan 22 Methotrexate 21 Tacrolimus 20 Radiotherapy 20 fludarabine 18 Cord Blood Stem Cell Transplantation 15 Methylprednisolone 14 Etoposide 13 Rivaroxaban 12 Granulocyte Colony-Stimulating Factor 12 apixaban 11 Daunorubicin 11 epoetin beta 10 Dalteparin 10 Thiotepa 9 Alemtuzumab 9 ferric carboxymaltose 8 eltrombopag 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01583218 2023-08-07

APEX

Alexion Pharmaceuticals, Inc.

Phase 3 Completed

7,513 enrolled 18 charts 1 FDA

Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡